Back to Rheumatology

OUR EXPERTISE AND SERVICES AVAILABLE IN

Ankylosing Spondylitis & nr-axSpA

Overview

Spherix’s coverage of the axial spondyloarthritis landscape assesses rheumatologist’s approach to treatment as well as non-radiographic axial spondyloarthritis with a special emphasis on the use of biologics and JAKs. We reserve a special section on gauging reactions to clinical trial results and their impact on future treatment preferences.

Services Available

Trending market evolution

  • Ankylosing Spondylitis & Non-Radiographic Axial Spondyloarthritis (US) - quarterly, n=100

  • Ankylosing Spondylitis & Non-Radiographic Axial Spondyloarthritis (EU) - semiannual, n=100

Benchmarking new brand performance

  • IL-17 Inhibitors in nr-axSpA (US) - Cosentyx (Novartis), Taltz (Eli Lilly)

  • Rinvoq (AbbVie) in Ankylosing Spondylitis (US)*

  • Xeljanz (Pfizer) in Ankylosing Spondylitis (US)*

*Pending approvals and launch

Gauging impact of disruptive events

  • Multi-Specialty Impact of COVID-19 (US)

Learn more about our services

  • HOW CAN WE PARTNER TOGETHER?

    Get more information on Ankylosing Spondylitis & nr-axSpA Coverage